Clinical trial Recruiting at 1 site Interventional Ages 40 and up

Improving ligament balance during total knee replacement

Official title: Ligament Balancing in Total Knee Arthroplasty - A Proof-of-Concept Study on a Systematic Approach to Bellemans Technique

Run by Oslo University Hospital · NCT06264076 · Data updated 2026-11-12

This tests a new surgical instrument to more predictably lengthen the medial collateral ligament (MCL) during total knee replacement for adults with varus knee osteoarthritis.

Quick facts

Study typeInterventional
Ages40 Years and up
SexAll
Enrollment40 (estimated)
SponsorOslo University Hospital
Academic / other
Locations2 sites (Bærums verk, Akershus and 1 other locations)
StatusRecruiting
StartedMay 1, 2024
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedNovember 25, 2025
Trial IDNCT06264076 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults over 40 undergoing primary total knee replacement for osteoarthritis or related indications with a varus deformity and who are otherwise in reasonable health are the intended candidates.

Probably not a fit

Patients undergoing revision or reoperation, those with considerable prior knee injury, isolated patellofemoral disease, or who do not require intraoperative ligament balancing are unlikely to benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a pilot interventional study of a novel device designed to standardize ligament lengthening of the MCL during total knee arthroplasty. Patients consent before surgery but are enrolled only if the surgeon finds that intraoperative ligament balancing is needed. The device is used during the operation to perform a controlled MCL lengthening and measurements are collected to compare repeatability and safety versus conventional techniques. Participants receive routine postoperative follow-up per the hospital's standard TKA protocol.

Why it matters

Potential benefit: If successful, the instrument could make medial ligament releases more consistent and reproducible, which may improve alignment and functional outcomes after knee replacement.

How similar studies have gone: Existing techniques such as Bellemans' pie-crusting and Whiteside's sequential releases are commonly used but show variable lengthening results, and using a dedicated instrument for more objective, repeatable MCL lengthening is relatively novel with limited prior data.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Men and women over 40 years of age that require total knee arthroplasty
* Idiopathic osteoarthrosis, osteonecrosis or avascular osteonecrosis
* Otherwise fairly healthy/ no significant health issues

Exclusion Criteria:

* Age under 40 years of age
* Pregnant
* Revisions or reoperations
* Considerable earlier injury to the knee
* Isolated patellofemoral osteoarthrosis

Where it's running

  • Oslo University Hospital, Ullevaal
    Oslo, Oslo, Norway
    Recruiting
  • Bærum Hospital, Vestre Viken Hospital Trust
    Bærums verk, Akershus, Norway
    Completed

Study contacts

  • Principal investigator: Lars HW Engseth, MD — Oslo University Hospital, Ullevaal, Oslo, Norway
  • Study coordinator: Lars HW Engseth, MD
  • Email: laengs@ous-hf.no
  • Phone: 004741254136

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.